EpiEndo Pharmaceuticals attending BIO International Convention in Boston

REYKJAVIK, ICELAND - 12 May 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of epithelial barrier-enhancing and anti-inflammatory drugs with a primary focus on chronic respiratory diseases, announces that CEO, Maria Bech, and CFO, Stefán Pétursson, will be attending the BIO International Convention from June 5-8 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

The BIO International Convention is the world's largest biotechnology event, attracting over 14,000 biotech and pharma leaders from around the world. With a focus on driving scientific innovation, the convention provides a useful platform for the EpiEndo team to connect with representatives across partnering and investment and to explore new possibilities.

During the event, EpiEndo will be highlighting its ground-breaking work in developing new treatments for inflammatory disorders. With over 1,500 exhibitors and a range of educational programming, attendees have the chance to connect, network, and learn about the latest advancements in biotech.

If you are interested in connecting with EpiEndo at the BIO International Convention, please get in touch via the partnering system: https://www.bio.org/events/bio-international-convention/one-one-partneringtm

- ENDS -

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity to reduce disease-causing inflammation.

Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin. A breakdown of this barrier is implicated in several chronic inflammatory diseases.

EpiEndo’s new class of orally available macrolide, with reduced AMR effect, known as a ‘BarriolideTM’, shows promise as a first-in-class therapeutic for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, is the first BarriolideTM to enter into Phase 2 clinical trials, for chronic obstructive pulmonary disease (COPD).

EP395, aims to be the first on-market oral, barrier strengthening and anti-inflammatory macrolide with reduced AMR effect, for the treatment of COPD, which has a significant unmet need. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD projected to cost $4.8 trillion by 2030.